Key result
Simvastatin significantly reduced systemic inflammation and multiple organ injury induced by zymosan in wild-type mice, but these protective effects were absent in PPARα knock-out mice.
Why the study?
Does simvastatin reduce systemic inflammation and organ injury in a zymosan-induced non-septic shock mouse model?
Does simvastatin reduce systemic inflammation and organ injury in a zymosan-induced non-septic shock mouse model?
p-value: p=<0.05
Simvastatin protects against molecular and cellular damage caused by systemic inflammation in a zymosan-induced non-septic shock model, with effects observed in both PPARαWT and PPARαKO mice.
No takes yet. Share an insight, caveat, or question.
Simvastatin's anti-inflammatory effects in murine zymosan shock require PPARα; hypothesis-generating and should not yet inform clinical practice.
Rinaldi et al. (2011) studied Zymosan-induced non-septic shock (n=80). Simvastatin vs. Vehicle (saline solution 0.9% NaCl) was evaluated on Systemic inflammation and organ injury (lung, liver, kidney, intestine) (p=<0.05). Simvastatin significantly reduced systemic inflammation and multiple organ injury induced by zymosan in wild-type mice, but these protective effects were absent in PPARα knock-out mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: